the potential of mrd-adapted treatment in multiple myeloma
Published 5 months ago • 295 plays • Length 4:38Download video MP4
Download video MP3
Similar videos
-
5:18
the value of mrd as a prognostic tool in myeloma
-
2:17
mrd: a promising biomarker in multiple myeloma
-
8:42
assessing mrd in multiple myeloma
-
1:37
the next steps and updated guidelines for the use of mrd concepts in multiple myeloma
-
1:26
mrd in myeloma: the fda perspective
-
1:37
mrd in myeloma
-
3:15
the evolution of mrd for myeloma
-
4:22
prognostic value of mrd and circulating plasma cells in myeloma
-
21:38
drawing the line: the rationale behind blood tube collection order
-
2:21
mezigdomide: a novel celmod showing promise in the treatment of r/r myeloma
-
1:46
novel quadruplet and triplet front-line options for early r/r multiple myeloma
-
0:52
mrd for multiple myeloma: is it ready for prime-time?
-
1:53
the future of multiple myeloma treatment
-
1:39
minimal residual disease (mrd) monitoring for multiple myeloma is here to stay
-
5:02
drug resistance in multiple myeloma
-
1:22
an all-molecular diagnostic approach for myeloma
-
1:33
tourmaline-mm3: undetectable mrd as an endpoint for maintenance therapy
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?
-
1:21
the value of sustained mrd negativity in mm
-
0:48
myeloma prognosis - the emergence of mrd
-
6:33
mrd as a tool to discontinue therapy in mm?
-
2:18
new applications for mrd measurement in myeloma: mrd 'over time'